<i>In Vitro</i>
            Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium

Badali, Hamid; Khodavaisy, Sadegh; Fakhim, Hamed; Hoog, G.S. de; Meis, Jacques F.; Chowdhary, Anuradha

doi:10.1128/aac.01733-15

Cited by 10 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the full range of species against which isavuconazole has activity and the clinical breakpoints have not yet been established. Nevertheless, previous studies have demonstrated MIC values of ≤4 μg/mL for many species closely related or identical to the rare pathogens in the current study . Although some isolates in the current study appeared to have reduced susceptibility in vitro compared with those prior studies, we cannot exclude the possibility of cross‐resistance in some patients who failed prior antifungal therapy.…”

Section: Discussioncontrasting

confidence: 74%

Isavuconazole for treatment of rare invasive fungal diseases

Cornely

Mullane

Ostrosky-Zeichner

et al. 2018

Mycoses

View full text Add to dashboard Cite

Data regarding treatment of rare invasive fungal diseases (IFDs) are scarce. We documented the efficacy and safety of isavuconazole for treatment of uncommonly diagnosed IFDs. VITAL was a single-arm, international, open-label study evaluating the efficacy and safety of isavuconazole (200 mg orally or intravenously every 8 hours for 48 hours, then once daily). The primary outcome was overall response at Day 42; key secondary outcomes were overall responses at Day 84 and end of treatment (EOT), mortality at Days 42 and 84, and safety. This analysis includes patients with IFD caused by rare or unidentified pathogens. Twenty-six patients with IFDs caused by rare moulds (n = 17), non-Candida yeasts (n = 2), or unidentified moulds (n = 7) were enrolled (median treatment duration [range], 114.5 [1-496]) days. Overall treatment success was observed in 11/26 (42.3%), 10/26 (38.5%), and 15/26 (57.7%) patients at Days 42, 84, and EOT, respectively. All-cause mortality rates were 2/26 patients (7.7%) at Day 42 and 4/26 patients (15.4%) at Day 84; another two patients died after Day 84. All patients had ≥1 treatment-emergent adverse event (TEAE); 15 patients (57.7%) had serious TEAEs, and TEAEs led to discontinuation of isavuconazole in four patients (15.4%). Isavuconazole may be efficacious for treatment of a range of rare IFDs.

show abstract

Section: Discussioncontrasting

confidence: 74%

Isavuconazole for treatment of rare invasive fungal diseases

Cornely

Mullane

Ostrosky-Zeichner

et al. 2018

Mycoses

View full text Add to dashboard Cite

show abstract

“…The in vitro susceptibility profile of Phaeoacremonium parasiticum has been proposed by Badali et al [ 20 ] and shows a similar pattern with Phaeoacremonium parasiticum isolated from the cornea of our patient. Phaeoacremonium parasiticum showed a low MIC for amphotericin B, voriconazole and posaconazole.…”

Section: Discussionsupporting

confidence: 87%

First report of a new corneal pathogen: Phaeoacremonium parasiticum

Massa

Riat²,

Panos

2020

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Keratitis is a public health issue in developing countries and a potentially sight-threatening condition. Collagen fibrils in the corneal stroma are parallels to each other. Fundamental substance maintains the same space between collagen fibrils. That is how corneal transparency can be achieved. Any damage which can modify this structure will lead to corneal opacity and loss of vision. Fungal keratitis might appear in up to one-third of cases. Nevertheless, fungal keratitis remains poorly described and understood. Herein, we present the first ever reported case of corneal infection due to Phaeoacremonium parasiticum in a young patient. We describe the clinical and microbial characteristics, and we also discuss the use of confocal microscopy in early diagnosis of this infection.

show abstract

“…has been found to be more susceptible in vitro than Fusarium spp. [ 23 ]. This finding prevented unnecessary combination anti-fungal therapy and simplified the regimen for the patient.…”

Section: Resultsmentioning

confidence: 99%

Fungal Whole-Genome Sequencing for Species Identification: From Test Development to Clinical Utilization

Salem-Bango

Price

Chan

et al. 2023

JoF

View full text Add to dashboard Cite

Using next-generation sequencing (NGS), we developed and validated a whole-genome sequencing (WGS)-based clinical test for fungal species identification on clinical isolates. The identification is mainly based on the fungal ribosomal internal transcribed spacer (ITS) region as the primary marker, and additional marker and genomic analysis applied for species within the Mucorales family (using the 28S rRNA gene) and Aspergillus genus (using the beta-tubulin gene and k-mer tree-based phylogenetic clustering). The validation study involving 74 unique fungal isolates (22 yeasts, 51 molds, and 1 mushroom-forming fungus) showed high accuracy, with 100% (74/74) concordance on the genus-level identifications and 89.2% (66/74) concordance on the species level. The 8 discrepant results were due to either the limitation of conventional morphology-based methodology or taxonomic changes. After one year of implementation in our clinical laboratory, this fungal NGS test was utilized in 29 cases; the majority of them were transplant and cancer patients. We demonstrated the utility of this test by detailing five case studies, in which accurate fungal species identification led to correct diagnosis, treatment adjustment or was ruled out for hospital acquired infection. This study provides a model for validation and implementation of WGS for fungal identification in a complex health system that serves a large immunocompromised patient population.

show abstract

In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium

Cited by 10 publications

References 31 publications

Isavuconazole for treatment of rare invasive fungal diseases

Isavuconazole for treatment of rare invasive fungal diseases

First report of a new corneal pathogen: Phaeoacremonium parasiticum

Fungal Whole-Genome Sequencing for Species Identification: From Test Development to Clinical Utilization

Contact Info

Product

Resources

About